GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0032640 | Stomach | GC | tumor necrosis factor production | 22/1159 | 181/18723 | 1.88e-03 | 1.94e-02 | 22 |
GO:0032680 | Stomach | GC | regulation of tumor necrosis factor production | 22/1159 | 181/18723 | 1.88e-03 | 1.94e-02 | 22 |
GO:00060064 | Stomach | GC | glucose metabolic process | 23/1159 | 196/18723 | 2.39e-03 | 2.29e-02 | 23 |
GO:0071706 | Stomach | GC | tumor necrosis factor superfamily cytokine production | 22/1159 | 186/18723 | 2.66e-03 | 2.46e-02 | 22 |
GO:1903555 | Stomach | GC | regulation of tumor necrosis factor superfamily cytokine production | 22/1159 | 186/18723 | 2.66e-03 | 2.46e-02 | 22 |
GO:00506734 | Stomach | GC | epithelial cell proliferation | 42/1159 | 437/18723 | 3.13e-03 | 2.78e-02 | 42 |
GO:0051602 | Stomach | GC | response to electrical stimulus | 8/1159 | 42/18723 | 3.77e-03 | 3.19e-02 | 8 |
GO:00027903 | Stomach | GC | peptide secretion | 26/1159 | 242/18723 | 4.39e-03 | 3.60e-02 | 26 |
GO:0090277 | Stomach | GC | positive regulation of peptide hormone secretion | 14/1159 | 103/18723 | 4.42e-03 | 3.60e-02 | 14 |
GO:19016535 | Stomach | GC | cellular response to peptide | 35/1159 | 359/18723 | 5.29e-03 | 4.15e-02 | 35 |
GO:00076235 | Stomach | GC | circadian rhythm | 23/1159 | 210/18723 | 5.64e-03 | 4.34e-02 | 23 |
GO:0002793 | Stomach | GC | positive regulation of peptide secretion | 14/1159 | 106/18723 | 5.72e-03 | 4.39e-02 | 14 |
GO:0035774 | Stomach | GC | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 7/1159 | 36/18723 | 5.87e-03 | 4.44e-02 | 7 |
GO:00300723 | Stomach | GC | peptide hormone secretion | 25/1159 | 236/18723 | 6.15e-03 | 4.64e-02 | 25 |
GO:00507965 | Stomach | GC | regulation of insulin secretion | 19/1159 | 165/18723 | 6.67e-03 | 4.86e-02 | 19 |
GO:000701511 | Stomach | CAG with IM | actin filament organization | 62/1050 | 442/18723 | 2.23e-11 | 4.96e-09 | 62 |
GO:00075861 | Stomach | CAG with IM | digestion | 29/1050 | 137/18723 | 4.42e-10 | 6.93e-08 | 29 |
GO:002260011 | Stomach | CAG with IM | digestive system process | 22/1050 | 104/18723 | 5.62e-08 | 4.16e-06 | 22 |
GO:003428411 | Stomach | CAG with IM | response to monosaccharide | 33/1050 | 225/18723 | 3.92e-07 | 2.30e-05 | 33 |
GO:000974611 | Stomach | CAG with IM | response to hexose | 32/1050 | 219/18723 | 6.38e-07 | 3.36e-05 | 32 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04935 | Colorectum | MSS | Growth hormone synthesis, secretion and action | 42/1875 | 120/8465 | 8.17e-04 | 5.16e-03 | 3.16e-03 | 42 |
hsa049351 | Colorectum | MSS | Growth hormone synthesis, secretion and action | 42/1875 | 120/8465 | 8.17e-04 | 5.16e-03 | 3.16e-03 | 42 |
hsa049352 | Colorectum | FAP | Growth hormone synthesis, secretion and action | 34/1404 | 120/8465 | 8.12e-04 | 5.14e-03 | 3.13e-03 | 34 |
hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa049353 | Colorectum | FAP | Growth hormone synthesis, secretion and action | 34/1404 | 120/8465 | 8.12e-04 | 5.14e-03 | 3.13e-03 | 34 |
hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa049354 | Colorectum | CRC | Growth hormone synthesis, secretion and action | 27/1091 | 120/8465 | 2.37e-03 | 1.69e-02 | 1.14e-02 | 27 |
hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
hsa049355 | Colorectum | CRC | Growth hormone synthesis, secretion and action | 27/1091 | 120/8465 | 2.37e-03 | 1.69e-02 | 1.14e-02 | 27 |
hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GHR | SNV | Missense_Mutation | | c.1288N>A | p.Leu430Ile | p.L430I | | protein_coding | deleterious(0.03) | possibly_damaging(0.506) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GHR | SNV | Missense_Mutation | novel | c.1859N>T | p.Ala620Val | p.A620V | | protein_coding | tolerated(0.24) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GHR | SNV | Missense_Mutation | | c.402N>G | p.Ile134Met | p.I134M | | protein_coding | tolerated(0.38) | probably_damaging(0.985) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
GHR | insertion | Nonsense_Mutation | novel | c.151_152insCCTTAGCCCCGAGGTAGTGTCTAGGGGTGGGGTGCCTGCAACCCC | p.Lys51delinsThrLeuAlaProArgTerCysLeuGlyValGlyCysLeuGlnProGln | p.K51delinsTLAPR*CLGVGCLQPQ | | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GHR | insertion | Frame_Shift_Ins | novel | c.1715_1716insCAAAATGAGATCTATG | p.Tyr573LysfsTer29 | p.Y573Kfs*29 | | protein_coding | | | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
GHR | insertion | Frame_Shift_Ins | novel | c.804_805insT | p.Asp269Ter | p.D269* | | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
GHR | deletion | Frame_Shift_Del | novel | c.302delN | p.Trp101Ter | p.W101* | | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GHR | SNV | Missense_Mutation | | c.113G>C | p.Arg38Thr | p.R38T | | protein_coding | tolerated_low_confidence(0.26) | benign(0.075) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GHR | SNV | Missense_Mutation | | c.1759N>A | p.Gly587Arg | p.G587R | | protein_coding | tolerated(0.36) | possibly_damaging(0.453) | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
GHR | SNV | Missense_Mutation | rs775194712 | c.1853C>T | p.Ala618Val | p.A618V | | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-EX-A3L1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | Syntropin | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | EP-51216 | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | ACCCRETROPIN | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | BVT-A | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | Pegvisomant | PEGVISOMANT | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | ACP-001 | ACP-001 | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | AOD9604 | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | 178101641 | | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | antagonist | CHEMBL1201515 | PEGVISOMANT | |
2690 | GHR | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | CHEMBL1201620 | SOMATREM | |